Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-209-FSP-B4
- Development stage
- Unknown
- Lead developer
- Nouscom
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-209-FSP-B4 is a viral vector-based cancer vaccine component developed by Nouscom. It is the Modified Vaccinia Ankara (MVA) boost component of the NOUS-209 genetic vaccine platform. NOUS-209 is designed to target 209 shared neoantigens, specifically frameshift peptides (FSPs), which result from mutations in microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) tumors. The vaccine regimen typically involves a heterologous prime-boost strategy, where a Great Ape Adenovirus (GAd) vector (GAd20-209-FSP) is used for priming and MVA-209-FSP-B4 is used for boosting. This approach is intended to induce a robust, broad, and long-lasting CD8+ and CD4+ T-cell response against the tumor. It is currently being evaluated in clinical trials for MSI-H colorectal, gastric, and endometrial cancers, often in combination with checkpoint inhibitors like pembrolizumab.
- Other names
- Modified Vaccinia Ankara-209-Frameshift Peptides
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on MVA-209-FSP-B4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-209-FSP-B4.